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Life Expectancy of Patients
With Low-Normal Thyroid Function
To the Editor Using the multistate life table method with data
from the Rotterdam Study, Bano and colleagues,1 in a recent
issueof JAMAInternalMedicine, showedthatparticipantswith
low-normal thyroid functionhad longer life expectancy com-
pared with those with high-normal thyroid function. Al-
though we agree that the results of this study would contrib-
ute to reevaluating the reference range of thyroid hormones,
Banoandcolleagues1 need toprovidemore informationabout
the association between thyroid hormone levels (within ref-
erence range) and mortality.
Bano et al1 calculated life expectancy among tertiles of
thyrotropin and free thyroxine considering the following 3
transitions: (1) incident cardiovascular disease (CVD), (2)
mortality among those without CVD, and (3) mortality
among those with CVD. It means that participants who
already had a history of CVD at baseline and those who
acquired CVD during the study period contributed to the
number of “persons at risk” of mortality among those with
CVD. However, it is not clear whether the effect of baseline
thyroid hormone levels on mortality risk would last after the
CVD event or would be homogenous among those who
already had a history of CVD at baseline and those who
acquired CVD during the study period. It is also unclear why
person-years at risk are different between the 2 transitions:
(1) incident CVD and (2) mortality among those without CVD.
Providing the additional information, the comparison
between the results of this study1 and those of previous
studies would be more straightforward.2,3
It has been reported that subclinical hypothyroidism is
associated with increased risk of CVD and mortality.4 More-
over, we previously reported that low-normal thyroid func-
tion had higher risks of cardiovascular and all-cause mortal-
ity than median-normal thyroid function.3 Physiologically,
low thyroid function has been known to weaken cardiac
function and increase systemic vascular resistance by regu-
lating calcium uptake and inducing endothelial dysfunc-
tion, which can eventually cause CVD.5 Additionally, the
association between low thyroid function and metabolic
syndrome has been reported within the reference range.3
Therefore, Bano et al1 would need to explain how they inter-
preted the prolonged life expectancy of participants with
low-normal thyroid function despite these physiological
mechanisms.
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In Reply We would like to thank Dr Inoue and colleagues for
their interest in our recent Original Investigation.1 As sug-
gested by Inoue and colleagues, we now provide some addi-
tional information about our analyses. Our life expectancy
calculations used age-adjusted hazards and age-specific
mortality rates, based on the data of individuals at different
ages and different health states. In the third transition (ie,
mortality among those with cardiovascular disease [CVD]),
stratified analyses among participants who acquired CVD
during the study period and participants who already had a
history of CVD at baseline consistently showed that high-
normal thyroid function is linked to a higher mortality risk
than low-normal thyroid function. In addition, sensitivity
analyses restricting the follow-up time to different lengths
(ie, 6, 8, 10 years of follow-up) yielded similar results. These
data point toward a persistent effect of thyroid hormones on
mortality risk across time.
Both the first and the second transition included partici-
pantswhowere freeofCVDatbaseline. Participants in the first
transition (ie, incidentCVD)were followedupuntil the occur-
rence of CVD events, whereas those in the second transition
(ie,mortality among thosewithoutCVD)were followedupun-
til they died. As a consequence, person-years at riskwere dif-
ferent between the 2 transitions.
We agree with Dr Inoue and colleagues that low thyroid
function has a negative effect on cardiovascular health. Ac-
cording to a large meta-analysis from the Thyroid Studies
Collaboration,2 patientswith subclinical hypothyroidismand
thyrotropin levels above 10 mIU/L have an increased risk of
coronary heart disease. However, it is unclear to what extent
these deleterious effects can be extended to lower thyrotro-
pin levels. Future studies aiming to define the optimal refer-
ence ranges of thyrotropin and free thyroxine are warranted.
Also, adequately powered randomized clinical trials focusing
on the treatment of subclinical hypothyroidism in relation to
CVD need to provide more robust evidence.
Our study1 showed that at the age of 50 years, individuals
with low-normal thyroid function live longer than thosewith
high-normal thyroid function. This is in line with other
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studies performed in middle-aged and older adults, suggest-
ing that the risk of CVD and mortality increases from low-
normal tohigh-normal thyroid function.3,4Suchfindings,how-
ever, may not be generalizable to younger populations.
We concur with Dr Inoue and colleagues that low-
normal thyroid function has been linked to metabolic syn-
drome. Our results, however, did not materially change
after accounting for metabolic syndrome components,
including diabetes, blood pressure, body mass index, and
lipid levels. Other factors beyond metabolic syndrome and
its components therefore likely explain our findings. Within
the reference range of thyroid function, differences in lon-
gevity can reflect differences in the risk of adverse out-
comes. So far, lower thyrotropin and higher free thyroxine
levels within the euthyroid range have been prospectively
linked to an increased risk of atrial fibrillation, atheroscle-
rotic CVD, heart failure and dementia, which are all associ-
ated with an increased risk of mortality.4-6
Arjola Bano, MD, MSc, DSc
Robin P. Peeters, MD, PhD
Oscar H. Franco, MD, PhD
Author Affiliations:Department of Internal Medicine, Erasmus University
Medical Center, Rotterdam, the Netherlands (Bano, Peeters); Academic Center
for Thyroid Diseases, Erasmus University Medical Center, Rotterdam,
the Netherlands (Bano, Peeters); Department of Epidemiology,
Erasmus University Medical Center, Rotterdam, the Netherlands
(Bano, Peeters, Franco).
Corresponding Author: Robin P. Peeters, MD, PhD, Department of Internal
Medicine, Rm Ee 502a, ErasmusMedical Center, Dr Molewaterplein 50,
Rotterdam 3015 GE, The Netherlands (r.peeters@erasmusmc.nl).
Conflict of Interest Disclosures:None reported.
1. Bano A, Dhana K, Chaker L, et al. Association of thyroid function with life
expectancy with and without cardiovascular disease: the Rotterdam study.
JAMA Intern Med. 2017;177(11):1650-1657.
2. Rodondi N, den ElzenWP, Bauer DC, et al; Thyroid Studies Collaboration.
Subclinical hypothyroidism and the risk of coronary heart disease andmortality.
JAMA. 2010;304(12):1365-1374.
3. Pereg D, Tirosh A, Elis A, et al. Mortality and coronary heart disease in
euthyroid patients. Am JMed. 2012;125(8):826.e7-826.e12.
4. Cappola AR, Arnold AM,Wulczyn K, CarlsonM, Robbins J, Psaty BM. Thyroid
function in the euthyroid range and adverse outcomes in older adults. J Clin
Endocrinol Metab. 2015;100(3):1088-1096.
5. Bano A, Chaker L, Mattace-Raso FUS, et al. Thyroid function and the risk of
atherosclerotic cardiovascular morbidity andmortality: the Rotterdam study.
Circ Res. 2017;121(12):1392-1400.
6. Chaker L, Wolters FJ, Bos D, et al. Thyroid function and the risk of dementia:
the Rotterdam study.Neurology. 2016;87(16):1688-1695.
DisagreementWith theNICEDecision
To the Editor In an Invited Commentary1 accompanying our
Original Investigation,2 both published in a recent issue of
JAMA Internal Medicine, Villines and Shaw1 emphasize find-
ings that they feel support theNational Institute forHealthand
CareExcellence (NICE)decision to recommendcoronary com-
puted tomographic angiography (CCTA) as the initial test for
patients with suspected coronary artery disease (CAD). Their
argument focuses on the statistically significant reduction in
myocardial infarction (MI).Wedisagreewith their interpreta-
tion and conclusion.
First, the MI reduction observed in our analysis2 is the
least robust of all the end points. While it met statistical
significance, it is not likely to be clinically important.
The relative risk reduction of 29% corresponds to an abso-
lute risk reduction of only 0.4%. If the MI reduction were
clinically relevant, it should translate to lower all-cause
mortality or cardiac hospitalizations. It did not. What is
more, the lower MI signal in our analysis was highly sensi-
tive to the inclusion of the SCOT-HEART trial,3 excluding
that it causes the relative risk to increase from 71% to 88%
(95% CI, 0.70-1.21).1 This is the only end point in our analy-
sis that does not pass sensitivity testing of individual trial
exclusion.
Villines and Shaw1 posit that CCTA-driven increases in
preventive therapies led to fewer MIs. That is possible but
even this is likely due to performance bias from individual
trial design. If patients in both groups were systematically
managed by protocols that specified the use of preventative
therapies based on standard guidelines, it is unknown what
the true difference in aspirin and statin prescribing would
have been and whether it would have affected hard end
points. For instance, in the FACTOR-64 trial,4 CCTA screen-
ing did not improve outcomes in asymptomatic patients
with diabetes where both groups were managed by pre-
specified protocols.
Villines and Shaw1 also overlook the excess use of inva-
sive procedures in the CCTA group.3 For every 1000 patients
who undergo CCTA instead of stress testing, an additional 30
to 40 patients will undergo invasive angiography and
revascularization.3 The consequences of this excess use, in-
cluding cost, procedural complications, and bleeding related
todual antiplatelet therapy,werenot formally assessed in any
of the individual trials.
Finally, Villines and Shaw1 do not address incidental ex-
tracardiac findingswithCCTA,whichmayoccur in44%ofpa-
tients, according toonemeta-analysis.5 Incidental findings in-
creasepatientanxietyandpromoteovertestingandareunlikely
to improve outcomes.
For these reasons,wedonotsupport theNICEdecisionand
believe that functional stress testing should remain the first
test for evaluating patients with chest pain.
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